COVID-19 Treatment: COVI-SHIELD (Neutralizing Antibody Cocktail)

Sorrento is developing a Neutralizing Antibody Cocktail to bind to distinct epitopes on SARS-CoV-2 Spike protein. The antibody cocktail potentially creates a high barrier to emergence of resistant variants in treated individuals. COVI-SHIELD mAbs Fc regions are engineered to eliminate interactions with host Fc receptors, thereby decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2 infection.